The endocrine system is made up of several glands such as pineal, pituitary, and thyroid and secretory organs such as hypothalamus and pancreas. These glands secrete hormones such as luteinizing hormone (LH), insulin, follicle stimulating hormone (FSH), and estradiol directly into the blood stream for the proper regulation of a number of bodily functions such as growth and homeostasis. Endocrine testing is done on biological samples to regulate the levels of endocrine hormones and to detect any deviation in hormone production. Less secretion (hyposecretion) or excess secretion (hypersecretion) can lead to a number of endocrine disorders such as menopause, infertility, and thyroid dysfunction.
Business intelligence firm Transparency Market Research, in a recent publication, states that the global endocrine testing market is anticipated to expand at a healthy CAGR of 8.50% from 2015 to 2023, rising from a value of US$6.1 bn in 2014 to US$12.8 bn in 2023.
Breakthrough Made by Scientists at Glasgow University Could Mean Better Endocrine Testing
A major discovery made by a team of researchers in the United Kingdom is believed to have the potential for improved endocrine testing and the testing and treatment of pancreatic cancer. According to the American Cancer Society, pancreatic cancer is one of the biggest health concerns in America, with over 48,000 Americans diagnosed with the disease last year.
Scientists at the University of Glasgow have discovered that pancreatic cancer is actually four separate diseases and each one requires different diagnoses and therapies. The scientists found that there are four primary genetic errors – classified as pancreatic progenitor, squamous-type, aberrantly differentiated endocrine exocrine, and immunogenic – that have resulted in the growth of tumors in the 456 patients studied in the experiment. The discovery of these errors, researchers believe, will be able to help speed up efforts in the development of newer forms of pancreatic cancer treatment.
Browse Press Release:
http://www.transparencymarketresearch.com/pressrelease/endocrine-testing-market.htm
http://www.transparencymarketresearch.com/pressrelease/endocrine-testing-market.htm
Endocrine Testing Market: Oligopolistic Nature of Competitive Landscape
By nature, the competitive landscape of the global endocrine testing market is immensely oligopolistic with the top five vendors making up a whopping 90% of the overall market. In 2014, F-Hoffman La Roche Ltd. dominated the scene with a share of 23.10% in the global market, driven by increased market penetration and a wide product portfolio. Abbott Laboratories came in second with a share of 19.30% in 2014, fueled by a broad range of technological platforms. DiaSorin, Agilent Technologies, and Siemens Healthcare followed next with a share of 16.80%, 15.40%, and 13.80% respectively. These companies are propelled by the presence of a broad array of endocrine testing technologies and products. Accounting for a combined share of 11.60% in the overall revenue in 2014 were players such as Bio Rad Laboratories, AB SCIEX LLC, Sysmex Corporation, Lab Corporation, Quest Diagnostics, Biomedical Diagnostics, Ortho-clinical Diagnostics, Thermo Fisher Scientific, and bioMerieux.
No comments:
Post a Comment